Medicare AdvantageCoverageMedium impact
MA07.008e, Stem-Cell Therapy/Platelet-Rich Plasma for Orthopedic Applications and Platelet-Rich Plasma/Platelet-Derived Growth Factor for Wound Healing and Other Miscellaneous Non-Orthopedic Conditions
Independence Blue Cross·Orthopedics, Wound Care, General Surgery +2 more·Medical Policy
Effective date
Mar 5, 2025
We identified it
Jun 19, 2026
Summary
Policy MA07.008e was reissued effective 03/05/2025, addressing coverage for stem-cell therapy and platelet-rich plasma (PRP) for orthopedic applications, and PRP/platelet-derived growth factor for wound healing and non-orthopedic conditions. The billing team must review the specific coverage criteria, medical necessity requirements, and any prior authorization mandates outlined in the full policy text to ensure compliant claim submission.
Action Required
By 03/05/2025: Billing team must obtain and review the complete MA07.008e policy document from the provided URL to identify specific CPT/HCPCS codes affected, prior authorization requirements, covered indications, and documentation standards for stem-cell therapy and PRP treatments. Update billing system rules, encounter forms, and prior authorization workflows accordingly. Communicate coverage requirements to providers to prevent claim denials for non-covered applications or missing medical necessity documentation.